First dual-acting anti-inflammatory and anti-fibrotic candidate in development for FSCD, a condition with no approved therapiesTopline safety, ...
First dual-acting anti-inflammatory and anti-fibrotic candidate in development for FSCD, a condition with no approved therapies Topline safety, PK, and PD data anticipated in Q1 2026 Advances ongoing ...
SunRock Biopharma, a biotechnology company focused on developing next-generation therapeutic antibodies, and Chime Biologics, ...
US FDA approves expanded paediatric indications for Celltrion’s Yuflyma and unbranded adalimumab-aaty: Incheon, South Korea Monday, October 20, 2025, 17:00 Hrs [IST] Celltrion, ...
Risk for venous thromboembolism (VTE) after an operation for colorectal cancer (CRC) is higher among patients with inflammatory bowel disease (IBD), according to results of a population-based cohort ...
Prebiotic foods include asparagus, Jerusalem artichokes, jicama, leeks, onions, garlic, apples, bananas, kefir, whole-grain ...
FDA approval based on superiority of Gazyva over standard therapy alone, as shown in Phase II NOBILITY and Phase III REGENCY data –– Gazyva is the only anti-CD20 monoclonal antibody to demonstrate a ...
The label update provides an option for patients who have received at least 1 approved systemic therapy if TNF blockers are clinically inadvisable.
Glucose-Lowering Medication Classes and Cardiovascular Outcomes in Patients With Type 2 Diabetes 1. In patients with type 2 ...
In Q3, the top 10 TV ad spenders poured a combined $544.8 million into airing their commercials, according to data shared ...
Tecentriq reduced the risk of death by 41% and the risk of disease recurrence or death by 36% compared with placebo –– ...
A recurrence risk of less than 0.5% at 6 years after surgery may provide a practical definition of “cure” in the setting of colon cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback